| Literature DB >> 34947271 |
Lavinia Berta1, Năstaca-Alina Coman2, Aura Rusu3, Corneliu Tanase4.
Abstract
The study of bimetallic nanoparticles (BNPs) has constantly been expanding, especially in the last decade. The biosynthesis of BNPs mediated by natural extracts is simple, low-cost, and safe for the environment. Plant extracts contain phenolic compounds that act as reducing agents (flavonoids, terpenoids, tannins, and alkaloids) and stabilising ligands moieties (carbonyl, carboxyl, and amine groups), useful in the green synthesis of nanoparticles (NPs), and are free of toxic by-products. Noble bimetallic NPs (containing silver, gold, platinum, and palladium) have potential for biomedical applications due to their safety, stability in the biological environment, and low toxicity. They substantially impact human health (applications in medicine and pharmacy) due to the proven biological effects (catalytic, antioxidant, antibacterial, antidiabetic, antitumor, hepatoprotective, and regenerative activity). To the best of our knowledge, there are no review papers in the literature on the synthesis and characterisation of plant-mediated BNPs and their pharmacological potential. Thus, an effort has been made to provide a clear perspective on the synthesis of BNPs and the antioxidant, antibacterial, anticancer, antidiabetic, and size/shape-dependent applications of BNPs. Furthermore, we discussed the factors that influence BNPs biosyntheses such as pH, temperature, time, metal ion concentration, and plant extract.Entities:
Keywords: anticancer; antimicrobial; bimetallic nanoparticles (BNPs); green synthesis; phytochemicals; polyphenols
Year: 2021 PMID: 34947271 PMCID: PMC8705710 DOI: 10.3390/ma14247677
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Synthesis of bimetallic nanoparticles (BNPs) mediated by the extract plants.
| Type of BNPs | Plant Species: Scientific Name (Family)—Common Name | Salt Concentration | Report | Synthesis Temperature | Time | Size | Shape | Ref. |
|---|---|---|---|---|---|---|---|---|
| Au–Ag BNPs | 1 mM AgNO3
| 1:5:5 | 70–80 °C | 60 | 25.9 | spherical | [ | |
| 5 mM AgNO3 | 1:1:1 | 65 °C | 720, 1080 and 1440 | 50 | spherical, triangular, hexagonal | [ | ||
| 1 mM HAuCl4 | 1:5:5 | irradiation with a frequency of 2.45 GHz and a power of 700 w | 20 | 10–50 | spherical | [ | ||
| 1 mM AgNO3 | 1:2:3 | 25 °C | 25 | 109 | spherical | [ | ||
| 1 mM AgNO3 | 1:1:1 | 70–80 °C | 60 | 15 | spherical | [ | ||
| 3 mM AgNO3 | 1:1:1 | solar heating | - | 15 | spherical | [ | ||
| 1 mM HAuCl4 | 1:2:2 | 25 °C | 120 | 20–80 | spherical, rod, triangular | [ | ||
| 1 mM HAuCl4 | 1:10:10 | Ultrasonic liquid processors | 40 | 34–66 | spherical | [ | ||
| 1 mM AgNO3 | 1:10:10 | 25 °C | 10 | 10 | spherical | [ | ||
| 10 mM HAuCl4·3H2O | 2:9:1 | 25 °C | 120 | 5–12 | spherical | [ | ||
| 1 mM AgNO3 | 1:15:15 | 30 °C | 120 | 3.0–45.0 | spherical | [ | ||
| Ag–Pt BNPs | 1 mM AgNO3
| 1:5:5 | 85 °C | 60 | 35.5 ± 0.8 | spherical | [ | |
| 1 mM AgNO3 | 1:2:2 | 100 °C | 60 | 36 | spherical | [ | ||
| Ag–Pd BNPs | 0.01 M PdCl2 | - | 25 °C | 60 | 20–70 | spherical | [ | |
| 1 mM AgNO3 | 1:4:4 | 25 °C | 60 | 15–30 | cubic | [ | ||
| 1 mM AgNO3 | 1:4:4 | 25 °C | 60 | 11.9 ± 0.8 | spherical | [ | ||
| 1:1:1 | 9.1 ± 0.7 | |||||||
| 1:1:3 | 7.4 ± 0.4 | |||||||
| 1 mM AgNO3 | 1:2:2 | 25 °C | 20 | 15.03–21.60 | spherical | [ | ||
| Au–Pd BNPs | 0.2 mM HAuCl4 | 1:1:1 | 50 °C | 120 | 80 | spherical | [ | |
| 0.25 mM HAuCl4 | 1:2:2 | 25 °C | 120 | 7.4 | spherical | [ | ||
| 5 mM HAuCl4 | 1:4:4 | 25 °C | 30 | 47.8 | flower-like core-shell | [ | ||
| 1 mM PdCl2 | 1:9:9 | 25 °C | 5 | 2–10 | spherical | [ | ||
| Au–Pt BNPs | 1 mM HAuCl4 | 1:1:1 | 80 °C | 1440 | 5–6 | spherical | [ | |
| 1 mM HAuCl4 | 1:5:5 | 85 °C | 60 | 35.1 ± 2.71 | flower-like | [ | ||
| Pt–Pd BNPs | H2PtCl6·6H2O | 1:1:3 | 100 °C | 120 | 3.97–7.06 | spherical | [ | |
| 1 mM H2PtCl6·6H2O | 1:1:1 | 100 °C | 300 | 20–25 | irregular shape | [ | ||
| Cu–Ag BNPs | 1 mM CuCl2·H2O, 1 mM AgNO3 | 1:1:2 | 120 °C | 60–360 | 10 | spherical | [ | |
| 10 mM AgNO3 | 5:2:15 | 90 °C | 180 | 40–50 | spherical | [ | ||
| ZnO–Ag BNPs | Zn(O2CCH3)2 | 1:1:1 | 60 ± 5 °C | 120 | 19.3–67.4 | spherical | [ | |
| Ag–Ni BNPs | AgNO3 | 1:5:5 | 700 °C | 10 | 10.25 ± 4.19 | pseudo-cubic | [ |
The biological activity of BNPs and metallic NPs synthesised from natural extracts depending on the NPs size (BNPs—bimetallic nanoparticles, NPs—nanoparticles, IC—half-maximal inhibitory concentration, GAE—gallic acid equivalents, FRAP—ferric-reducing antioxidant power).
| Plant Extract | NPs | Size | Experimental Findings | Ref. |
|---|---|---|---|---|
|
| Ag–Pd BNPs | 20 nm | 48.45 ± 0.04 μg/mL (IC50–A549) | [ |
| Ag NPs | 20–40 nm | 18.09 ± 0.012 μg/mL (IC50–A549) | ||
| Pd NPs | 20–40 nm | 15.09 ± 0.012 μg/mL (IC50–A549) | ||
|
| Au–Ag BNPs | 14.9 nm | 5.75 × 10−16 µM (IC50–HeLa) | [ |
| Au NPs | 78 nm | 0.0027 µM (IC50–HeLa) | ||
| Ag NPs | 23.5 nm | 9.1 × 10−9 µM (IC50–HeLa) | ||
|
| Au–Ag BNPs | 10 nm | 5.33 ± 0.33 mm (zone of inhibition— | [ |
| Au NPs | 20 nm | 8.33 ± 0.33 mm (zone of inhibition— | ||
| Ag NPs | 20 nm | 7.66 ± 0.33 mm (zone of inhibition— | ||
|
| Ag–Pt BNPs | 35.5 ± 0.8 nm | 44.1 mg GAE/g (FRAP) | [ |
| Ag NPs | 33.4 ± 1.0 nm | 18.5 mg GAE/g (FRAP) | ||
| Pt NPs | 32 nm | 16.5 mg GAE/g (FRAP) | ||
|
| Au–Pt BNPs | 5–6 nm | excellent catalytic activity | [ |
| Au NPs | 10 nm | - | ||
| Pt NPs | 15 nm | - | ||
|
| Pt–Pd BNPs | 25 nm | 74.25% anticancer activity (HeLa) | [ |
| Pt NPs | 2.5 nm | 12.6% anticancer activity (HeLa) | ||
| Pd NPs | 10 nm | 33.15% anticancer activity (HeLa) | ||
|
| Au–Ag BNPs | 5–12 nm | excellent catalytic activity | [ |
| Au NPs | 10–20 nm | - | ||
| Ag NPs | 10–20 nm | - | ||
|
| Ag–Pt BNPs | 36 nm | 100.1 ± 0.32 μg/mL (zone of inhibition— | [ |
| Ag NPs | 32 nm | 150.6 ± 0.41 μg/mL (zone of inhibition— | ||
| Pt NPs | 30 nm | 154.2 ± 0.34 μg/mL (zone of inhibition— |
Figure 1Applications of bimetallic nanoparticles (BNPs) mediated by plant extracts (created with BioRender.com (accessed on 27 September 2021)) [29].
Figure 2General mechanisms for the antimicrobial mode of action of bimetallic nanoparticles (BNPs) (created with BioRender.com (accessed on 27 September 2021)) [29].
Figure 3Treatment of tumour cells by bimetallic nanoparticles (BNPs).
Biological activity of bimetallic nanoparticles (BNPs).
| Plant Extract | BNPs Types | Size | Activity | Ref. |
|---|---|---|---|---|
|
| Cu–Ag | 10 nm | Antimicrobial activities against Gram-negative bacteria ( | [ |
|
| Ag–Au | 14.9 nm | (In vitro) anticancer activity against HeLa cells. | [ |
|
| Au–Ag | 10–20 nm | Anticancer activity against HeLa cells. Antibacterial and antifungal activity. Catalytic activity against Congo red and 4-nitrophenol. | [ |
|
| Au–Ag | 10–20 nm | Antibacterial against | [ |
|
| Au–Ag | 25.9 nm | Catalytic activity. | [ |
|
| Ag–Ni | 23.67 nm | Antioxidant activity. | [ |
|
| Ag–Au | 9–14 nm | Anticancer activity against the MCF7 cell line. | [ |
|
| Cu–Ag | 10–20 nm | The cytotoxic effect of biohybrid nanomaterials on different cell lines, MDA-MB-231, HeLa, SiHa, and He-G2 and non-toxic against Vero (normal epithelial cells). | [ |
|
| Ag–Pt | 36.0 nm | Antioxidant and antibacterial against Gram-positive and Gram-negative bacteria. Cytotoxic effect against pathogenic microbes and MCF-7 breast cancer cell line. | [ |
|
| Au–Ag | 34–66 nm | Improving wound healing in vivo were examined in models of Swiss bee mice. | [ |
|
| Au–Ag | 20–80 nm | Bactericidal activity against selective oral pathogenic bacteria ( | [ |
|
| ZnO–Ag | 19.3–67.4 nm | Antioxidant, antibacterial, and antileishmanial activity. | [ |
|
| Ag–Mn | 3.3 nm | Antibacterial activity against | [ |
|
| Ag–Cu | ≈60 nm | Nanocomposites showed good antibacterial activity against Gram-positive and Gram-negative. | [ |
|
| Au–Ag | 15–20 nm | Electrochemical biosensor for the development of a respiration sensor for the detection of early gastric cancer. | [ |
|
| Au–Ag | 20–50 nm | Catalyst for the reduction of 4-nitrophenol to 4-aminophenol. | [ |
|
| Ag–Pt | 35.5 ± 0.8 nm, Spherical | Antimicrobial activity and antioxidant activity against DPPH and ABTS. | [ |
|
| Ag–Pt | 20 nm | Anticancer activity against human lung cancer A549 cells. Antibacterial activity against MRSA and | [ |
|
| Au–Ag | 10–50 nm | Antibacterial and immunomodulatory activity. | [ |
|
| Au–Pd | 2 nm | Larvicidal activity against mosquito larvae ( | [ |
|
| Ag–Cu | 80–100 nm | Antibacterial activity against | [ |
|
| Ag–Cu | 87 nm | Antibacterial activity against | [ |
|
| Ag–Co | - | Larvicidal activity against | [ |
|
| Ag–Au | 50 nm | Evaluation of cytotoxicity. | [ |
|
| Au–Ag | 48.79–83.44 nm | Antibacterial activity and antileishmanial activity against | [ |
|
| Ag–Cu | 30 nm | Antidiabetic, antioxidant, and antibacterial activity. | [ |
|
| Au–Ag | 15 nm | Significant antioxidant activity. | [ |
|
| Ag–Cu | ≈20–40 nm | Investigated in vitro toxicity studies. | [ |
|
| Cu–Ag | 26 nm | Catalytic activity for dye degradation (methylene blue) and antibacterial testing. | [ |
| Quercetin and gallic acid | Ag–Se | 30–35 nm | Antitumor effect on the proliferation/viability of Dalton lymphoma cell lines. | [ |